drugset / Trial / NCT04602117
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.
Timeline
- Start
- 2021-07-28
- Primary completion
- 2021-11-17
- Completion
- 2021-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Trastuzumab duocarmazine | Other / unclassified | — | Intravenous |